CagriSema did not meet the noninferiority threshold for weight loss compared with tirzepatide in a phase 3 trial of patients with obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results